Jadwiga A Wedzicha Selected Research

Glycopyrrolate (Glycopyrronium Bromide)

8/2021	Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial.
1/2021	Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials.
1/2021	Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
1/2020	Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
1/2020	Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
1/2019	Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
1/2019	Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
1/2018	Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
1/2018	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
1/2018	Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jadwiga A Wedzicha Research Topics

Disease

132	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 05/2002
14	Inflammation (Inflammations) 01/2021 - 05/2002
10	Infections 11/2021 - 05/2002
8	Pneumonia (Pneumonitis) 01/2020 - 01/2008
5	Bacterial Infections (Bacterial Infection) 11/2021 - 07/2014
5	Respiratory Insufficiency (Respiratory Failure) 01/2017 - 12/2002
3	Asthma (Bronchial Asthma) 01/2022 - 12/2012
3	Virus Diseases (Viral Diseases) 11/2021 - 01/2014
3	Obstructive Lung Diseases (Obstructive Lung Disease) 01/2021 - 06/2014
3	Disease Progression 03/2014 - 12/2003
2	Dyspnea (Shortness of Breath) 08/2021 - 01/2020
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2021 - 01/2019
2	Eosinophilia 01/2020 - 11/2017
2	Chronic Disease (Chronic Diseases) 01/2016 - 02/2009
2	Cough 01/2016 - 10/2015
2	Fatigue 01/2016 - 02/2009
1	Obstructive Sleep Apnea 01/2022
1	Lung Diseases (Lung Disease) 08/2021
1	COVID-19 02/2021
1	Respiratory Syncytial Virus Infections 10/2020
1	Dysbiosis 01/2019
1	Hypercapnia 01/2017

Drug/Important Bio-Agent (IBA)

30	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 09/2007
19	Biomarkers (Surrogate Marker)IBA 11/2021 - 10/2006
18	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 08/2021 - 05/2013
17	Bronchodilator Agents (Bronchodilators)IBA 01/2020 - 09/2007
15	indacaterolIBA 01/2021 - 05/2013
15	GoldIBA 10/2020 - 09/2010
12	Fluticasone (Cutivate)FDA LinkGeneric 01/2021 - 09/2007
11	Anti-Bacterial Agents (Antibiotics)IBA 11/2021 - 04/2008
11	Salmeterol Xinafoate (Serevent)FDA Link 01/2021 - 09/2007
11	Muscarinic AntagonistsIBA 01/2020 - 05/2013
8	Tiotropium Bromide (Spiriva)FDA Link 10/2020 - 09/2007
7	C-Reactive ProteinIBA 01/2020 - 01/2006
5	Formoterol Fumarate (Oxis)FDA Link 08/2021 - 01/2013
5	Interleukin-8 (Interleukin 8)IBA 10/2020 - 12/2003
5	SteroidsIBA 01/2020 - 09/2007
5	CytokinesIBA 01/2019 - 05/2002
5	Oxygen (Dioxygen)IBA 01/2017 - 08/2004
4	Environmental Pollutants (Pollutants, Environmental)IBA 01/2021 - 12/2003
4	Interleukin-6 (Interleukin 6)IBA 10/2020 - 05/2002
4	RoflumilastIBA 01/2017 - 01/2010
4	indacaterol-glycopyrronium combinationIBA 10/2014 - 05/2013
3	budesonide-glycopyrrolate-formoterol fumarate drug combinationIBA 08/2021 - 10/2019
3	Budesonide (Pulmicort)FDA LinkGeneric 08/2021 - 01/2020
3	SmokeIBA 01/2021 - 01/2011
3	AntioxidantsIBA 01/2019 - 10/2017
3	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 01/2016 - 01/2010
2	Antiviral Agents (Antivirals)IBA 11/2021 - 10/2008
2	Peroxidase (Myeloperoxidase)IBA 10/2020 - 01/2006
2	AntibodiesIBA 10/2020 - 01/2018
2	16S Ribosomal RNAIBA 07/2020 - 01/2018
2	TabletsIBA 01/2020 - 10/2015
2	GlucocorticoidsIBA 01/2020 - 01/2016
2	erdosteineIBA 01/2019 - 10/2017
2	Particulate MatterIBA 01/2019 - 07/2011
2	Fluticasone-Salmeterol Drug Combination (Advair)FDA Link 01/2019 - 01/2017
2	OzoneIBA 01/2019 - 07/2011
2	InterleukinsIBA 01/2016 - 04/2005
2	EnzymesIBA 01/2016 - 04/2014
2	Moxifloxacin (Avelox)FDA Link 10/2015 - 01/2010
2	Beclomethasone (Beclometasone)FDA Link 08/2015 - 01/2013
2	Fibrinogen (Factor I)FDA Link 09/2014 - 01/2004
2	Brain Natriuretic Peptide (Natrecor)FDA Link 11/2013 - 04/2012
2	Erythromycin (Erycette)FDA LinkGeneric 01/2009 - 12/2008
1	beta-Galactosidase (Lactaid)IBA 01/2022
1	VaccinesIBA 01/2022
1	AlkanesIBA 11/2021
1	decaneIBA 11/2021
1	Volatile Organic CompoundsIBA 11/2021
1	Interferon Type IIBA 02/2021
1	Pancreatic Elastase (Elastase)IBA 02/2021
1	Immunoglobulin A (IgA)IBA 10/2020
1	Neutralizing AntibodiesIBA 10/2020
1	tiotropium-olodaterolIBA 10/2020
1	Opioid Analgesics (Opioids)IBA 01/2020
1	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2020
1	SuspensionsIBA 10/2019
1	Macrophage Colony-Stimulating FactorIBA 10/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2019
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2019
1	Antimicrobial PeptidesIBA 01/2019
1	Cathepsin DIBA 01/2019
1	NitrogenIBA 01/2019
1	Nitrogen OxidesIBA 01/2019
1	OxidesIBA 01/2019
1	Poly I-CIBA 01/2019
1	CathelicidinsIBA 01/2019
1	Indicators and Reagents (Reagents)IBA 01/2018
1	MucinsIBA 01/2017

Therapy/Procedure

51	Therapeutics 01/2022 - 05/2002
6	Nebulizers and Vaporizers (Inhaler) 01/2021 - 12/2007
2	Noninvasive Ventilation 01/2017 - 01/2017
2	Drug Therapy (Chemotherapy) 01/2016 - 12/2012
2	Length of Stay 01/2016 - 12/2012
2	Positive-Pressure Respiration (Positive End-Expiratory Pressure) 12/2012 - 01/2003
2	Secondary Prevention 06/2004 - 12/2003
1	Retreatment 01/2020
1	Metered Dose Inhalers (Metered Dose Inhaler) 10/2019
1	Artificial Respiration (Mechanical Ventilation) 01/2017